Elite in Astrocytoma

Anthony J. Chalmers

Glasgow, SCT, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Astrocytoma
Glasgow, SCT, GB 
OverviewLocationsClinical Research

Overview

Anthony Chalmers practices in Glasgow, United Kingdom. Mr. Chalmers is rated as an Elite expert by MediFind in the treatment of Astrocytoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 47 articles and participated in 1 clinical trial in the study of Astrocytoma.

Gender
Male

Locations

Glasgow, SCT G611QH, United Kingdom
Other Locations
Garscube Estate, Switchback Road, Bearsden, SCT G611QH, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients with Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients with Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
Enrollment Status: Recruiting
Publish Date: December 13, 2024
Intervention Type: Other
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
Enrollment Status: Completed
Publish Date: February 05, 2018
Intervention Type: Drug, Procedure, Genetic, Other
Study Phase: Phase 1
View 1 Less Clinical Trial

116 Total Publications

Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival.
Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival.
Journal: Clinical and translational radiation oncology
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chalmers's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile